

## NC Pharmacy Prior Approval Request for Triptans

### Beneficiary Information

1. Beneficiary Last Name: \_\_\_\_\_ 2. First Name: \_\_\_\_\_  
3. Beneficiary ID #: \_\_\_\_\_ 4. Beneficiary Date of Birth: \_\_\_\_\_ 5. Beneficiary Gender: \_\_\_\_\_

### Prescriber Information

6. Prescribing Provider NPI #: \_\_\_\_\_  
7. Requester Contact Information - Name: \_\_\_\_\_ Phone #: \_\_\_\_\_ Ext. \_\_\_\_\_

### Drug Information

8. Drug Name: \_\_\_\_\_ 9. Strength: \_\_\_\_\_ 10. Quantity Per 30 Days: \_\_\_\_\_  
11. Length of Therapy (in days):  up to 30 days  60 Days  90 Days  120 Days  180 Days  365 Days  Other \_\_\_\_\_

### Clinical Information

#### Request for Non-Preferred Drug:

1. Failed two preferred drug(s). List preferred drugs failed: \_\_\_\_\_  
1a.  Allergic Reaction 1b.  Drug-to-drug interaction. Please describe reaction: \_\_\_\_\_
2. Previous episode of an unacceptable side effect or therapeutic failure. Please provide clinical information:  
\_\_\_\_\_
3. Clinical contraindication, co-morbidity, or unique patient circumstance as a contraindication to preferred drug(s). Please provide clinical information: \_\_\_\_\_
4. Age specific indications. Please give patient age and explain: \_\_\_\_\_
5. Unique clinical indication supported by FDA approval or peer reviewed literature. Please explain and provide a general reference:  
\_\_\_\_\_
6. Unacceptable clinical risk associated with therapeutic change. Please explain: \_\_\_\_\_

#### Request for Exceeding Quantity Limit (Exceeding 12 per 30 days):

7. Does the patient have a diagnosis of migraine or cluster headache?  Yes  No
8. Does the patient have more than 6 moderate or severe headache?  Yes  No
9. Does the patient have a history of NSAID therapy in the past year?  Yes  No
10. Does the patient have a contraindication or allergy to NSAID therapy?  Yes  No
11. Is the patient currently receiving therapy with a migraine preventative?  Yes  No
12. Does the patient have a contraindication or history of an adverse reaction with preventative medications?  Yes  No  
Please list: \_\_\_\_\_
13. Did the patient have no clinical benefit after at least a 90 day trial of preventative medications at the maximum tolerated dose?  
 Yes  No
14. Has the patient been diagnosed with Ischemic Heart Disease, Peripheral Vascular Disease, Cerebrovascular Disease, Ischemic Bowel Disease, or Hemiplegic Migraine?  Yes  No
15. Has the patient received an MAO Inhibitor in the past 2 weeks?  Yes  No
16. Will the beneficiary have concurrent use of (or use within 24 hours) ergotamine-containing or ergot-type medication?  
 Yes  No
17. Will the beneficiary have concurrent use of (or use within 24 hours) another 5- HT1 agonist?  Yes  No
18. Does the patient have uncontrolled hypertension or basilar migraine?  Yes  No
19. Has the prescriber reviewed the DHB evidenced-based recommendations on the treatment of migraine?  Yes  No

Signature of Prescriber: \_\_\_\_\_ Date: \_\_\_\_\_  
(Prescriber Signature Mandatory)

I certify that the information provided is accurate and complete to the best of my knowledge, and I understand that any falsification, omission, or concealment of material fact may subject me to civil or criminal liability.